- Home
- JRVR vs HUMA Comparison
JRVR vs HUMA Comparison
Compare JRVR & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JRVR | HUMA |
|---|---|---|
| Founded | 2002 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.9M | 191.4M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | JRVR | HUMA |
|---|---|---|
| Price | $4.35 | $0.56 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $7.33 | $6.19 |
| AVG Volume (30 Days) | 235.2K | ★ 5.4M |
| Earning Date | 05-04-2026 | 05-15-2026 |
| Dividend Yield | ★ 0.64% | N/A |
| EPS Growth | ★ 125.82 | 79.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $687,614,000.00 | $2,038,000.00 |
| Revenue This Year | N/A | $444.16 |
| Revenue Next Year | $1.61 | $248.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.76 | $0.55 |
| 52 Week High | $7.20 | $2.55 |
Technical Indicators
Market Signals| Indicator | JRVR | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 44.12 | 33.67 |
| Support Level | $4.35 | $0.55 |
| Resistance Level | $4.36 | $1.24 |
| Average True Range (ATR) | 0.16 | 0.05 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 47.69 | 0.00 |
Price Performance
Historical ComparisonAbout JRVR James River Group Holdings Ltd.
James River Group Holdings Inc is a holding company that owns and operates a group of specialty insurance companies focused on underwriting small and middle market casualty risks within the U.S. excess and surplus (E&S) lines market. The Company operates in two specialty property-casualty insurance segments: Excess and Surplus Lines and Specialty Admitted Insurance.
About HUMA Humacyte Inc.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.